US Medical Innovations, LLC

US Medical Innovations, LLC (USMI), headquartered in Takoma Park, Maryland, develops advanced surgical and oncological technologies focused on cold plasma ablation and robotic surgical systems. The company manufactures the Canady Helios™ Cold Plasma Ablation System, an FDA 510(k)-cleared device (K240297) designed for soft tissue ablation during surgical procedures, particularly for treating positive microscopic margins in solid tumor resection without damaging adjacent normal tissue. USMI also produces the Canady Flex RoboWrist™, an FDA-approved robotic surgical device for use in open and laparoscopic procedures. The company has completed Phase I IDE clinical trials demonstrating statistically significant efficacy in treating advanced and recurrent solid tumors (Stage 4), with peer-reviewed results published in MDPI's Cancers journal. USMI is affiliated with the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and operates as a biomedical and life sciences subsidiary of US Patent Innovations, LLC. The company serves surgical oncologists, orthopedic surgeons, and general surgeons at major medical institutions including Rush University and international centers such as Sheeba Medical Center in Israel. Products employ cold atmospheric plasma physics technology for intraoperative tissue ablation and are positioned for oncologic, orthopedic, and general surgical applications.